Prostate cancer is the second most common cancer for men in the United States (after skin cancer) and is the second leading cause of cancer deaths (after lung cancer). The American Cancer Society ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study. Researchers at Flinders University and the University of South Australia ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Scientists have learned that prostate cancers can vary significantly among patients and that there are often differences within each patient's tumor. However, the study published Aug. 28 in Nature ...

A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer cell models in the ...

Prostate cancer is the fifth leading cause of death from cancer (after lung, liver, colorectum and stomach) across the world and the third most common cause of death from male specific cancers in ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

To further confirm their findings, the scientists analyzed mouse models of prostate cancer driven by human MYC and found that the increased MYC activity leads to a cascade of alterations in ...